Mirus Bio applies gene transfer technologies to develop products for the pharmaceutical industry. Its reagent kits assist researchers with in vitro transfection, in vivo delivery, DNA and RNA labeling, and RNA interference. The company is also developing its own therapies based on its intravenous technology, called Pathway IV, that facilitates the delivery of plasmid DNA to targeted muscles. One of those therapies is MyoDys, a gene therapy designed to treat muscular dystrophy by delaying loss of muscle function. Mirus Bio is also developing treatments for peripheral ischemia and anemia. Hoffmann-La Roche acquired the company's discovery division for $125 million in 2008.